Scinai Immunotherapeutics
SCNI
8 hedge funds and large institutions have $689K invested in Scinai Immunotherapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 0 closing their positions.
320% more capital invested
Capital invested by funds: $164K → $689K (+$525K)
60% more funds holding
Funds holding: 5 → 8 (+3)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$221K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$216K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$159K |
| 4 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$20.5K |
| 5 |
VIA
Vantage Investment Advisors
State College,
Pennsylvania
|
+$16.4K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $192K | +$216K | +263 | +4,383% |
|
|
2
Renaissance Technologies
New York
| $192K | +$221K | +269 | New |
|
|
SM
3
Sabby Management
Miami Beach,
Florida
| $139K | +$159K | +194 | New |
|
|
VIA
4
Vantage Investment Advisors
State College,
Pennsylvania
| $136K | +$16.4K | +20 | +12% |
|
|
LTFS
5
Ladenburg Thalmann Financial Services
Miami,
Florida
| $18K | +$20.5K | +25 | New |
|
6
Wells Fargo
San Francisco,
California
| $7K | +$2.46K | +3 | +43% |
|
7
Morgan Stanley
New York
| $3K | +$2.46K | +3 | +150% |
|
|
EWM
8
Edge Wealth Management
New York
| $2K | – | – | – |
|
SCNI Hedge Fund Activity: Q3 2017 in Review
8 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q3 2017, worth a combined $689K — up 320% from $164K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SCNI positions and 0 closed out — a net gain of 3 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $221K.
- 8 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q3 2017, up from 5 in Q2 2017.
- Funds reported $689K of Scinai Immunotherapeutics stock for Q3 2017, up 320% quarter-over-quarter.
- 3 funds opened new Scinai Immunotherapeutics positions in Q3 2017 and 0 closed out, a net change of +3 holders.
- The largest Scinai Immunotherapeutics buyer in Q3 2017 was Renaissance Technologies, an estimated $221K added.
Based on aggregated 13F filings for Q3 2017.